Medscape2d
New COPD Treatments Shift Focus From Symptoms to Survival
With 30% of COPD cases misdiagnosed, experts call for improved diagnostic strategies, better disease classification, and ...
BCBSOK could impact asthma patients needing injections
Oklahomans with severe asthma who are insured with BlueCross and BlueShield of Oklahoma (BCBSOK), may have to give themselves ...
pharmaphorum1d
FDA says no to AZ's Fasenra for nasal polyp indication
AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...
pharmaphorum1d
GSK’s twice-yearly asthma drug clears two phase 3 trials
More than 50% of patients with severe asthma have high eosinophil levels, making them candidates for biologic therapies like Nucala and other drugs like AstraZeneca’s Fasenra (benralizumab ...
BCBS of Oklahoma requiring insured asthma patients to do their own medicine injections
Blue Cross Blue Shield of Oklahoma (BCBS), including BCBS plans in states of Illinois, New Mexico, Texas and Montana, is ...
pulmonologyadvisor3d
Colby Stong
Researchers examined whether the C-reactive-protein-to-albumin ratio was a useful biomarker for predicting COPD risk.